Avoro Capital Advisors PTCT Position
Active9-Fund ConvergenceAvoro Capital Advisors initiated a new position in PTC Therapeutics Inc. (PTCT) in Q4 2025, holding $52.0M worth of shares across 685,000 shares.
PTCT is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for PTC923 in 75 days (Jun 30, 2026), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 12.2% of float with 7.2 days to cover, indicating significant bearish positioning against Avoro Capital's long thesis.
About PTC Therapeutics Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Full company profile →Short Interest
12.2%
7.2 days to cover
Frequently Asked Questions
Does Avoro Capital Advisors own PTCT?
Yes. As of Q4 2025, Avoro Capital Advisors holds 685,000 shares of PTC Therapeutics Inc. (PTCT) valued at $52.0M. This data comes from their SEC 13F filing.
How many hedge funds own PTCT?
9 specialist biotech hedge funds currently hold PTCT, including RTW Investments, Tang Capital Management, Driehaus Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy PTCT?
Avoro Capital Advisors's position in PTCT was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's PTCT position increasing or decreasing?
Avoro Capital Advisors initiated a new position in PTCT in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PTCTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →